Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental pill aims to rev up immune system against Hard-to-Treat tumors

NCT ID NCT05270213

Recruiting now Disease control Sponsor: Riboscience, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental drug called RBS2418, taken as a pill, to see if it can help the immune system fight advanced cancers that have spread or come back. The study involves 164 adults with various solid tumors who have already tried standard treatments. Some participants will receive RBS2418 alone, while others will get it combined with the immunotherapy drug pembrolizumab or other standard cancer therapies. The main goals are to check safety, find the best dose, and look for early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RBS2418 (an experimental immune modulator pill) and pembrolizumab (an immunotherapy drug)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 164 participants, so it is primarily testing safety and dosing. It may not lead to an effective treatment, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer metastatic neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

  • American Oncology Partners of Maryland

    RECRUITING

    Bethesda, Maryland, 20817, United States

    Contact Email: •••••@•••••

  • Carolina BioOncology Institute

    COMPLETED

    Huntersville, North Carolina, 28078, United States

  • Christiana Care Health Services

    RECRUITING

    Newark, Delaware, 19713, United States

    Contact Email: •••••@•••••

  • Honor Health Research Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

    Contact Email: •••••@•••••

  • Ichan School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

    Contact Email: •••••@•••••

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    RECRUITING

    Baltimore, Maryland, 21224, United States

    Contact Email: •••••@•••••

  • NEXT Virigina

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Email: •••••@•••••

  • Norton Cancer Institute

    RECRUITING

    Louisville, Kentucky, 40202, United States

    Contact Email: •••••@•••••

  • Ochsner Clinic Foundation

    RECRUITING

    New Orleans, Louisiana, 70121, United States

    Contact Email: •••••@•••••

  • Stanford Cancer Institute

    RECRUITING

    Palo Alto, California, 94305, United States

    Contact Email: •••••@•••••

  • Tranquil Research

    WITHDRAWN

    Webster, Texas, 77598, United States

  • UCLA Hematology/Oncology - Santa Monica

    RECRUITING

    Santa Monica, California, 90404, United States

    Contact Email: •••••@•••••

  • University of Arizona

    RECRUITING

    Tucson, Arizona, 85724, United States

    Contact Email: •••••@•••••

  • Vanderbilt-Ingram Cancer Center

    RECRUITING

    Nashville, Tennessee, 37235, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.